Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease - Christensen, B; Micic, D; Gibson, P R (Aliment Pharmacol Ther, 2018)
, et al.